Boehringer Ingelheim’s blood thinner Pradaxa has snagged a comfortable seat among its newer anticoagulant rivals thanks to recent Food and Drug Administration (FDA) rulings. In 2010, Pradaxa became the first in the Factor Xa inhibitor class to hit the market. The drug was promoted as a more convenient alternative to the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. Warfarin requires users to be monitored on a regular basis. Prescriptions soared, and so did adverse reactions reports involving bleeding events, a risk not uncommon with blood thinners. But unlike warfarin, there was no FDA-approved antidote to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.